<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName A++V2.4.dtd?>
  <?SourceDTD.Version 2.4?>
  <?ConverterInfo.XSLTName springer2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Neural Transm</journal-id>
      <journal-title-group>
        <journal-title>Journal of Neural Transmission</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0300-9564</issn>
      <issn pub-type="epub">1435-1463</issn>
      <publisher>
        <publisher-name>Springer Vienna</publisher-name>
        <publisher-loc>Vienna</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3104009</article-id>
      <article-id pub-id-type="pmid">21298298</article-id>
      <article-id pub-id-type="publisher-id">585</article-id>
      <article-id pub-id-type="doi">10.1007/s00702-011-0585-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Basic Neurosciences, Genetics and Immunology - Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Poleszak</surname>
            <given-names>Ewa</given-names>
          </name>
          <address>
            <email>ewa.poleszak@umlub.pl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soca&#x142;a</surname>
            <given-names>Katarzyna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Szopa</surname>
            <given-names>Aleksandra</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wr&#xF3;bel</surname>
            <given-names>Andrzej</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Szewczyk</surname>
            <given-names>Bernadeta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kasperek</surname>
            <given-names>Regina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blicharska</surname>
            <given-names>Eliza</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nowak</surname>
            <given-names>Gabriel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wla&#x17A;</surname>
            <given-names>Piotr</given-names>
          </name>
          <address>
            <email>piotr.wlaz@umcs.lublin.pl</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Applied Pharmacy, Medical University of Lublin, Chod&#x17A;ki 1, 20-093 Lublin, Poland </aff>
        <aff id="Aff2"><label>2</label>Department of Animal Physiology, Institute of Biology, Maria Curie-Sk&#x142;odowska University, Akademicka 19, 20-033 Lublin, Poland </aff>
        <aff id="Aff3"><label>3</label>Second Department of Gynecology, Medical University of Lublin, Lublin, Poland </aff>
        <aff id="Aff4"><label>4</label>Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krak&#xF3;w, Poland </aff>
        <aff id="Aff5"><label>5</label>Department of Analytical Chemistry, Medical University of Lublin, Lublin, Poland </aff>
        <aff id="Aff6"><label>6</label>Department of Cytobiology, Jagiellonian University, Collegium Medicum, Krak&#xF3;w, Poland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>2</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>5</day>
        <month>2</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <volume>118</volume>
      <issue>6</issue>
      <fpage>857</fpage>
      <lpage>864</lpage>
      <history>
        <date date-type="received">
          <day>3</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>1</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>In the present study, we demonstrated that low, ineffective doses of <italic>N</italic>-methyl-<sc>d</sc>-aspartic acid (NMDA) receptor antagonists [competitive NMDA antagonist, CGP 37849, at 0.312&#xA0;mg/kg intraperitoneally (i.p.), antagonist of the glycine<sub>B</sub> sites, L-701,324, at 2&#xA0;mg/kg i.p., partial agonist of glycine<sub>B</sub> sites, <sc>d</sc>-cycloserine, at 2.5&#xA0;mg/kg i.p.] administered jointly with an ineffective dose of the benzodiazepine, chlordiazepoxide (CDP, 2.5&#xA0;mg/kg i.p.), significantly increased the percentage of time spent in the open arms of the elevated plus-maze (index of anxiolytic effect). Furthermore, CDP-induced anxiolytic-like activity (5&#xA0;mg/kg i.p.) was antagonized by NMDA (75&#xA0;mg/kg i.p.) and by an agonist of glycine<sub>B</sub> sites of the NMDA receptor complex, <sc>d</sc>-serine [100&#xA0;nmol/mouse intracerebroventricularly (i.c.v.)]. The present study showed a positive interaction between &#x3B3;-aminobutyric acid (GABA) and glutamate neurotransmission in the anxiolytic-like activity in the elevated plus-maze test in mice and this activity seems to particularly involve the NMDA receptors.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Chlordiazepoxide</kwd>
        <kwd>NMDA receptor ligands</kwd>
        <kwd>Anxiety</kwd>
        <kwd>Elevated plus-maze</kwd>
        <kwd>Mice</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>&#x3B3;-Aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system (Sieghart <xref ref-type="bibr" rid="CR41">1995</xref>; Sieghart et al. <xref ref-type="bibr" rid="CR42">1999</xref>). Dysfunction of the central GABA system has long been associated with anxiety spectrum disorders (Nutt and Malizia <xref ref-type="bibr" rid="CR30">2001</xref>; Lydiard <xref ref-type="bibr" rid="CR27">2003</xref>; Nemeroff <xref ref-type="bibr" rid="CR29">2003</xref>). It is known that in both, humans and animals, positive modulators of GABA<sub>A</sub> ionotropic receptors produce anxiolytic-like activity, while the negative modulators evoke anxiety (Kalueff and Nutt <xref ref-type="bibr" rid="CR16">1996</xref>; Nutt and Malizia <xref ref-type="bibr" rid="CR30">2001</xref>). Thus, for many years, the leading treatment of anxiety disorders was benzodiazepines that enhance GABAergic inhibitory neurotransmission through allosteric modulation of GABA<sub>A</sub> receptors. They are still preferred due to their efficacy, rapid onset of action, and safety (Stahl <xref ref-type="bibr" rid="CR43">2002</xref>), but their adverse effects: sedation, cognitive impairments, undesirable interactions with other drugs, drug dependence and abuse mostly limited their use (Uhlenhuth et al. <xref ref-type="bibr" rid="CR47">1999</xref>; Stahl <xref ref-type="bibr" rid="CR43">2002</xref>). Moreover, these treatments are effective only in about 70% of patients and full remission is observed only in 40% of patients; thus, the novel therapeutic strategies are extensively sought.</p>
      <p>Glutamate, which is the chief excitatory neurotransmitter in the mammalian central nervous system, is widely distributed throughout the brain and mediates its effects via stimulation of ionotropic and metabotropic receptors (Kew and Kemp <xref ref-type="bibr" rid="CR19">2005</xref>). The ionotropic glutamate receptor family is ligand-gated channels divided into three groups named after their selective agonists [<italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA), &#x3B1;-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), and kainate] and their density is high in cortical and limbic regions being implicated in the mediation of fear and anxiety (Krystal et al. <xref ref-type="bibr" rid="CR24">1999</xref>). The preclinical data indicate that a number of different classes of NMDA receptor antagonists, acting at specific sites located on the NMDA receptor complex, produced anxiolytic-like activity in tests of anxiety in rodents (Dunn et al. <xref ref-type="bibr" rid="CR8">1989</xref>; Sharma and Kulkarni <xref ref-type="bibr" rid="CR40">1993</xref>; P&#x142;a&#x17A;nik et al. <xref ref-type="bibr" rid="CR34">1994</xref>; Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>; Kotli&#x144;ska and Liljequist <xref ref-type="bibr" rid="CR23">1998</xref>; Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR38">2000</xref>; Poleszak et al. <xref ref-type="bibr" rid="CR35">2004</xref>). In humans, memantine and <sc>d</sc>-cycloserine are effective in obsessive&#x2013;compulsive disorder (Feusner et al. <xref ref-type="bibr" rid="CR11">2009</xref>; Abramowitz et al. <xref ref-type="bibr" rid="CR2">2009</xref>; Aboujaoude et al. <xref ref-type="bibr" rid="CR1">2009</xref>), and moreover, <sc>d</sc>-cycloserine was effective in post-traumatic stress disorder (Amiel and Mathew <xref ref-type="bibr" rid="CR3">2007</xref>). Despite these findings, the numerous adverse effects produced by competitive and non-competitive NMDA antagonist limited their potential clinical use (Tricklebank et al. <xref ref-type="bibr" rid="CR44">1989</xref>; Willetts et al. <xref ref-type="bibr" rid="CR49">1990</xref>). Profound side effects, typical for competitive and non-competitive NMDA receptor antagonist, do not occur after administration glycine<sub>B</sub> site modulators (Parsons et al. <xref ref-type="bibr" rid="CR31">1998</xref>). This modulatory site of the NMDA receptor complex is a co-agonist site with affinity for glycine and <sc>d</sc>-serine (Wood et al. <xref ref-type="bibr" rid="CR50">1989</xref>, <xref ref-type="bibr" rid="CR51">1996</xref>). Antagonists and partial agonist of glycine<sub>B</sub> sites inhibit the function of the NMDA receptor complex and produce effects which are similar to those produced by competitive and non-competitive NMDA receptor antagonist. It was shown that glycine potentiated the action of glutamate at NMDA receptors (Johnson and Ascher <xref ref-type="bibr" rid="CR15">1987</xref>), and antagonists and partial agonist of the glycine<sub>B</sub> sites inhibited the function of the NMDA receptor complex and produced anxiolytic-like action in several experimental models of anxiety (Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>; Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR37">1998</xref>; Kotli&#x144;ska and Liljequist <xref ref-type="bibr" rid="CR23">1998</xref>).</p>
      <p>In this study, we investigated the interaction between glycine<sub>B</sub> sites ligands and benzodiazepine/GABA<sub>A</sub> receptor ligand, chlordiazepoxide (CDP) in the elevated plus-maze test in mice.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Animals</title>
        <p>The experiments were carried out on adult male Albino Swiss mice (25&#x2013;30&#xA0;g) purchased from the licensed breeder (Ko&#x142;acz, Warsaw, Poland). The animals were kept in cages (up to 10 per cage) on a natural day&#x2013;night cycle with free access to food and water and they were used after at least 7&#xA0;days of acclimatization to laboratory conditions. Each experimental group consisted of 8&#x2013;12 animals. The experimental protocol was approved by the Local Ethics Committee at the Medical University of Lublin (license no. 31/2007), and all the procedures were in strict compliance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).</p>
      </sec>
      <sec id="Sec4">
        <title>Drug administration</title>
        <p>Chlordiazepoxide (CDP, Polfa-Pozna&#x144;, Poland) was administered intraperitoneally (i.p.) 60&#xA0;min before the test. L-701,324 (7-chloro-4-hydroxy-3-(3- phenoxy)phenylquinolin-2[1<italic>H</italic>]-one, Sigma) was suspended in a 1% aqueous solution of Tween 80 (POCH, Gliwice, Poland) and administered intraperitoneally (i.p.) 60&#xA0;min before the test. NMDA (Sigma), CGP 37849 (<sc>dl</sc>-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid, Tocris), <sc>d</sc>-cycloserine (<sc>d</sc>-4-amino-3-isoxazolidone, Sigma) were dissolved in 0.9% NaCl and administered i.p. and also administered 60&#xA0;min before the test. <sc>d</sc>-Serine (Sigma) was also dissolved in 0.9% NaCl and administered intracerebroventricularly (i.c.v.) 15&#xA0;min before the test. I.c.v. administration was performed according to a modified method described by Lipman and Spencer (<xref ref-type="bibr" rid="CR25">1980</xref>). Control animals received an i.p. or i.c.v. injection of a respective vehicle. The volume of vehicles or drug solutions for i.p. and i.c.v. administrations was 10&#xA0;ml/kg and 5&#xA0;&#x3BC;l per mouse, respectively.</p>
      </sec>
      <sec id="Sec5">
        <title>Elevated plus-maze test</title>
        <p>The experiments were carried out on mice according to the method of Lister (<xref ref-type="bibr" rid="CR26">1987</xref>). The plus-maze apparatus was made of black polyvinyl chloride and consisted of two open (30&#xA0;&#xD7;&#xA0;5&#xA0;cm) and two enclosed (30&#xA0;&#xD7;&#xA0;5&#xA0;&#xD7;&#xA0;15&#xA0;cm) arms. The arms extended from a central platform of 5&#xA0;&#xD7;&#xA0;5&#xA0;cm. The apparatus was mounted on a stable base raising it 38&#xA0;cm above the floor and was illuminated by red light. The test consisted of placing a mouse in the center of the apparatus (facing an enclosed arm) and allowing it to freely explore the maze. The number of entries into the open arms and the time spent in these arms were scored for a 5-min test period. An entry was defined as placing all four paws within the boundaries of the arm. The following measures were obtained from the test: the total number of arm entries, the percentage of entries into the open arms, the time spent in the open arms expressed as a percentage of the time spent in both the open and closed arms. Anxiolytic activity was indicated by increases in time spent in open arms or in a greater number of open arm entries. Total number of entries into either type of an arm was used as a measure of the overall motor activity.</p>
      </sec>
      <sec id="Sec6">
        <title>Statistical analysis</title>
        <p>The obtained data were evaluated by two-way analysis of variance (ANOVA) followed by Bonferroni&#x2019;s post hoc test. All results are presented as a mean&#xA0;&#xB1;&#xA0;standard error of the mean (SEM). A <italic>p</italic>&#xA0;&#x2264;&#xA0;0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <sec id="Sec8">
        <title>Anxiolytic-like effect of joint administration of CDP and CGP 37849 in the elevated plus-maze test</title>
        <p>Chlordiazepoxide administered at a dose of 0.5&#xA0;mg/kg or CGP 37849 administered at a dose of 0.312&#xA0;mg/kg, both given alone, did not change the percentage of the time spent and also entries into the open arms with the exception of CDP, which significantly increased this latter measure (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The joint administration of CDP and CGP 37849 significantly increased the percentage of the time spent in the open arms (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a) and enhanced the number of entries into open arms (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). A two-way ANOVA demonstrated lack of effect of CDP [<italic>F</italic>(1, 28)&#xA0;=&#xA0;1.91, <italic>p</italic>&#xA0;=&#xA0;0.1777], significant effect of CGP 37849 [<italic>F</italic>(1, 28)&#xA0;=&#xA0;26.38, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001] and significant interaction [<italic>F</italic>(1, 28)&#xA0;=&#xA0;8.02, <italic>p</italic>&#xA0;=&#xA0;0.0085] in the time spent in open arms, while a significant effect of CDP [<italic>F</italic>(1, 28)&#xA0;=&#xA0;15.301, <italic>p</italic>&#xA0;=&#xA0;0.0005], no effect of CGP 37849 [<italic>F</italic>(1, 28)&#xA0;=&#xA0;2.93, <italic>p</italic>&#xA0;=&#xA0;0.09882] and no interaction [<italic>F</italic>(1, 28)&#xA0;=&#xA0;0.0, <italic>p</italic>&#xA0;=&#xA0;0.9492] in the open arm entries.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Effect of joint administration of CGP 37849 and chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice [the percentage of the time spent in the open arms (<bold>a</bold>), and the percentage of the open arms entries (<bold>b</bold>)]. CGP 37849 and CDP was administered i.p. 60&#xA0;min before the test. The <italic>values</italic> represent the mean&#xA0;&#xB1;&#xA0;SEM (<italic>n</italic>&#xA0;=&#xA0;8 mice per group) *<italic>p</italic>&#xA0;&lt;&#xA0;0.05 versus CGP 37849, <sup>^</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.001 versus CDP, <sup>#</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.05 versus control (vehicle-treated group) (Bonferroni&#x2019;s test)</p></caption><graphic xlink:href="702_2011_585_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Anxiolytic-like effect of joint administration of CDP and L-701,324 in the elevated plus-maze test</title>
        <p>Chlordiazepoxide administered at a dose of 0.5&#xA0;mg/kg did not alter the percentage of time spent and increased entries into the open arms (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). L-701,324 given alone at a dose of 2&#xA0;mg/kg exhibited no effect in this test (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a, b). The joint administration of CDP and L-701,324 (both in ineffective per se doses) significantly increased the percentage of time spent in the open arms (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a), but not in the number of entries into open arms (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b). A two-way ANOVA demonstrated a significant effect of CDP [<italic>F</italic>(1, 28)&#xA0;=&#xA0;7.66, <italic>p</italic>&#xA0;=&#xA0;0.0099], a significant effect of L-701,324 [<italic>F</italic>(1, 28)&#xA0;=&#xA0;9.65, <italic>p</italic>&#xA0;&lt;&#xA0;0.0043] and not quite significant interaction [<italic>F</italic>(1, 28)&#xA0;=&#xA0;3.83, <italic>p</italic>&#xA0;=&#xA0;0.0603] in the time spent in open arms, while a significant effect of CDP [<italic>F</italic>(1, 28)&#xA0;=&#xA0;7.25, <italic>p</italic>&#xA0;=&#xA0;0.0118], no effect of L-701,324 [<italic>F</italic>(1, 28)&#xA0;=&#xA0;1.09, <italic>p</italic>&#xA0;=&#xA0;0.3056] and not quite significant interaction [<italic>F</italic>(1, 28)&#xA0;=&#xA0;3.77, <italic>p</italic>&#xA0;=&#xA0;0.0622] in the open arm entries.<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Effect of joint administration of L-701,324 and chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice [the percentage of the time spent in the open arms (<bold>a</bold>), and the percentage of the open arms entries (<bold>b</bold>)]. L-701,324 and CDP was administered i.p. 60&#xA0;min before the test. The <italic>values</italic> represent the mean&#xA0;&#xB1;&#xA0;SEM (<italic>n</italic>&#xA0;=&#xA0;8 mice per group) *<italic>p</italic>&#xA0;&lt;&#xA0;0.01 versus L-701,324, <sup>^</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.01 versus CDP, <sup>#</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.01 versus control (vehicle-treated group) (Bonferroni&#x2019;s test)</p></caption><graphic xlink:href="702_2011_585_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Anxiolytic-like effect of joint administration of CDP and <sc>d</sc>-cycloserine in the elevated plus-maze test</title>
        <p>Chlordiazepoxide administered at a dose of 0.5&#xA0;mg/kg did not change either the percentage of the time spent (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a) or the number of entries into open arms (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b). <sc>d</sc>-Cycloserine administered singly at a dose of 2.5&#xA0;mg/kg remained also without any effect on both of these measures (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). CDP administered at an ineffective per se dose of 0.5&#xA0;mg/kg and <sc>d</sc>-cycloserine administered at such a dose of 2.5&#xA0;mg/kg significantly increased the percentage of the time spent in the open arms (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a) and enhanced the number of entries into open arms (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b). A two-way ANOVA demonstrated a significant effect of CDP [<italic>F</italic>(1, 34)&#xA0;=&#xA0;24.83, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001], a significant effect of DCS [<italic>F</italic>(1, 34)&#xA0;=&#xA0;8.73, <italic>p</italic>&#xA0;=&#xA0;0.0057] and a significant interaction [<italic>F</italic>(1, 34)&#xA0;=&#xA0;13.35, <italic>p</italic>&#xA0;=&#xA0;0.0009] in the time spent in the open arms, while a significant effect of CDP [<italic>F</italic>(1, 34)&#xA0;=&#xA0;19.50, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001], a significant effect of DCS [<italic>F</italic>(1, 34)&#xA0;=&#xA0;4.31, <italic>p</italic>&#xA0;=&#xA0;0.0451] and no interaction [<italic>F</italic>(1, 34)&#xA0;=&#xA0;2.93, <italic>p</italic>&#xA0;=&#xA0;0.0956] in the open arm entries.<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Effect of joint administration of <sc>d</sc>-cycloserine (DCS) and chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice [the percentage of the time spent in the open arms (<bold>a</bold>), and the percentage of the open arms entries (<bold>b)</bold>]. L-701,324 and CDP was administered i.p. 60&#xA0;min before the test. The <italic>values</italic> represent the mean&#xA0;&#xB1;&#xA0;SEM (<italic>n</italic>&#xA0;=&#xA0;9&#x2013;10 mice per group) *<italic>p</italic>&#xA0;&lt;&#xA0;0.001 versus DCS, <sup>^</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.05, <sup>^^</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.001 versus CDP (Bonferroni&#x2019;s test)</p></caption><graphic xlink:href="702_2011_585_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Effect of NMDA on the anxiolytic-like activity of CDP in the elevated plus-maze test</title>
        <p>Chlordiazepoxide given at a dose of 2&#xA0;mg/kg produced anxiolytic-like effect significantly increasing the percentage of the time spent in the open arms and increasing the percentage of the entries into the open arms (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). The increase in percentage of the time spent in the open arms induced by CDP (2&#xA0;mg/kg) was significantly reversed by NMDA (75&#xA0;mg/kg) (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a). The increase in the number of the open arm entries induced by CDP (2&#xA0;mg/kg) was significantly decreased by NMDA (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>b). NMDA given alone had no effect on either the time spent or the entries into the open arms (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). A two-way ANOVA demonstrated a significant effect of CDP [<italic>F</italic>(1, 36)&#xA0;=&#xA0;45.98, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001], a significant effect of NMDA [<italic>F</italic>(1, 36)&#xA0;=&#xA0;21.37, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001] and a significant interaction [<italic>F</italic>(1, 36)&#xA0;=&#xA0;21.19, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001] in the time spent in open arms, and a similarly significant effect of CDP [<italic>F</italic>(1, 36&#xA0;=&#xA0;15.87, <italic>p</italic>&#xA0;=&#xA0;0.0003], a significant effect of NMDA [<italic>F</italic>(1, 36)&#xA0;=&#xA0;8.11, <italic>p</italic>&#xA0;=&#xA0;0.0072] and a significant interaction [<italic>F</italic>(1, 36)&#xA0;=&#xA0;11.91, <italic>p</italic>&#xA0;=&#xA0;0.0014] in the open arm entries.<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Effect of <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) on the action of chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice [the percentage of the time spent in the open arms (<bold>a</bold>) and the percentage of the open arms entries (<bold>b)</bold>]. NMDA and CDP was administered i.p. 60&#xA0;min before the test. The values represent the mean&#xA0;&#xB1;&#xA0;SEM (<italic>n</italic>&#xA0;=&#xA0;10 mice per group) *<italic>p</italic>&#xA0;&lt;&#xA0;0.001 versus CDP, <sup>#</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.001, versus control (vehicle-treated group) (Bonferroni&#x2019;s test)</p></caption><graphic xlink:href="702_2011_585_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
      <sec id="Sec12">
        <title>Effect of <sc>d</sc>-serine on the anxiolytic-like activity of CDP in the elevated plus-maze test</title>
        <p>Chlordiazepoxide given at a dose of 2&#xA0;mg/kg produced an anxiolytic-like effect significantly increasing the percentage of the time spent in the open arms and increasing the percentage of the entries into the open arms (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). The increase in the percentage of the time spent in the open arms induced by CDP (2&#xA0;mg/kg) was significantly reversed by <sc>d</sc>-serine (100&#xA0;nmol/mouse) (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>a). The increase in the number of the open arm entries induced by CDP (2&#xA0;mg/kg) was significantly changed by <sc>d</sc>-serine (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>b). <sc>d</sc>-Serine given alone had no effect on either the time spent or the entries into the open arms (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). A two-way ANOVA demonstrated a significant effect of CDP [<italic>F</italic>(1, 33)&#xA0;=&#xA0;23.80, <italic>p</italic>&#xA0;&lt;&#xA0;0.0001], a significant effect of <sc>d</sc>-serine [<italic>F</italic>(1, 33)&#xA0;=&#xA0;18.49, <italic>p</italic>&#xA0;=&#xA0;0.0001] and a significant interaction [<italic>F</italic>(1, 33)&#xA0;=&#xA0;16.33, <italic>p</italic>&#xA0;&lt;&#xA0;0.0003] in the time spent in the open arms, while a significant effect of CDP [<italic>F</italic>(1, 33)&#xA0;=&#xA0;4.97, <italic>p</italic>&#xA0;=&#xA0;0.0321], no effect of <sc>d</sc>-serine [<italic>F</italic>(1, 33)&#xA0;=&#xA0;2.93, <italic>p</italic>&#xA0;=&#xA0;0.0957] and a significant interaction [<italic>F</italic>(1, 33)&#xA0;=&#xA0;9.11, <italic>p</italic>&#xA0;=&#xA0;0.0046] in the open arm entries.<fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Effect of <sc>d</sc>-serine (DS) on the action of chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice [the percentage of the time spent in the open arms (<bold>a</bold>), and the percentage of the open arms entries (<bold>b</bold>)]. CDP was administered i.p. 60&#xA0;min before the test, DS was administered i.c.v. 45&#xA0;min after CDP injection. The <italic>values</italic> represent the mean&#xA0;&#xB1;&#xA0;SEM (<italic>n</italic>&#xA0;=&#xA0;9&#x2013;10 mice per group) *<italic>p</italic>&#xA0;&lt;&#xA0;0.01, **<italic>p</italic>&#xA0;&lt;&#xA0;0.001 versus CDP, <sup>#</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.01, <sup>##</sup><italic>p</italic>&#xA0;&lt;&#xA0;0.001, versus control (vehicle-treated group) (Bonferroni&#x2019;s test)</p></caption><graphic xlink:href="702_2011_585_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec13">
        <title>Effect of CDP and NMDA ligands on the total arm entries</title>
        <p>Chlordiazepoxide and all tested NMDA receptor ligands, administered singly or in combination, did not alter the number of the total arm entries (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). A two-way ANOVA demonstrated the lack of the significant interaction between treatments in all analyzed experiments A: <italic>F</italic>(1, 28)&#xA0;=&#xA0;0.74, <italic>p</italic>&#xA0;=&#xA0;0.3964, B: <italic>F</italic>(1, 28)&#xA0;=&#xA0;0.53, <italic>p</italic>&#xA0;=&#xA0;0.4723], C: <italic>F</italic>(1, 36)&#xA0;=&#xA0;3.25, <italic>p</italic>&#xA0;=&#xA0;0.0797, D: <italic>F</italic>(1, 36)&#xA0;=&#xA0;2.59, <italic>p</italic>&#xA0;=&#xA0;0.1164, E: <italic>F</italic>(1, 36)&#xA0;=&#xA0;1.02, <italic>p</italic>&#xA0;=&#xA0;0.3185.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>The number of the total arm entries for all experimental groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment and dose</th><th align="left">Number of total entries</th></tr></thead><tbody><tr><td align="left" colspan="2"><italic>A</italic></td></tr><tr><td align="left">Vehicle</td><td char="&#xB1;" align="char">12.63&#xA0;&#xB1;&#xA0;0.46</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg</td><td char="&#xB1;" align="char">12.00&#xA0;&#xB1;&#xA0;1.00</td></tr><tr><td align="left">CGP 37849 0.312&#xA0;mg/kg</td><td char="&#xB1;" align="char">13.25&#xA0;&#xB1;&#xA0;1.21</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg and CGP 37849 0.312&#xA0;mg/kg</td><td char="&#xB1;" align="char">14.75&#xA0;&#xB1;&#xA0;1.85</td></tr><tr><td align="left" colspan="2"><italic>B</italic></td></tr><tr><td align="left">Vehicle</td><td char="&#xB1;" align="char">14.38&#xA0;&#xB1;&#xA0;1.75</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg</td><td char="&#xB1;" align="char">15.75&#xA0;&#xB1;&#xA0;1.46</td></tr><tr><td align="left">L-701,324 2&#xA0;mg/kg</td><td char="&#xB1;" align="char">13.50&#xA0;&#xB1;&#xA0;1.04</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg and L-701,324&#xA0;mg/kg</td><td char="&#xB1;" align="char">16.75&#xA0;&#xB1;&#xA0;0.59</td></tr><tr><td align="left" colspan="2"><italic>C</italic></td></tr><tr><td align="left">Vehicle</td><td char="&#xB1;" align="char">14.50&#xA0;&#xB1;&#xA0;0.74</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg</td><td char="&#xB1;" align="char">11.44&#xA0;&#xB1;&#xA0;0.67</td></tr><tr><td align="left"><sc>d</sc>-cycloserine 2.5&#xA0;mg/kg</td><td char="&#xB1;" align="char">12.80&#xA0;&#xB1;&#xA0;0.70</td></tr><tr><td align="left">CDP 0.5&#xA0;mg/kg and <sc>d</sc>-cycloserine 2.5&#xA0;mg/kg</td><td char="&#xB1;" align="char">12.00&#xA0;&#xB1;&#xA0;0.92</td></tr><tr><td align="left" colspan="2"><italic>D</italic></td></tr><tr><td align="left">Vehicle</td><td char="&#xB1;" align="char">11.80&#xA0;&#xB1;&#xA0;1.07</td></tr><tr><td align="left">CDP 2&#xA0;mg/kg</td><td char="&#xB1;" align="char">15.30&#xA0;&#xB1;&#xA0;1.90</td></tr><tr><td align="left">NMDA 75&#xA0;mg/kg</td><td char="&#xB1;" align="char">13.20&#xA0;&#xB1;&#xA0;0.53</td></tr><tr><td align="left">CDP 2&#xA0;mg/kg and NMDA 75&#xA0;mg/kg</td><td char="&#xB1;" align="char">12.80&#xA0;&#xB1;&#xA0;0.92</td></tr><tr><td align="left" colspan="2"><italic>E</italic></td></tr><tr><td align="left">Vehicle</td><td char="&#xB1;" align="char">15.10&#xA0;&#xB1;&#xA0;1.65</td></tr><tr><td align="left">CDP 2&#xA0;mg/kg</td><td char="&#xB1;" align="char">19.30&#xA0;&#xB1;&#xA0;0.71</td></tr><tr><td align="left"><sc>d</sc>-serine 100&#xA0;nmol/mouse</td><td char="&#xB1;" align="char">12.40&#xA0;&#xB1;&#xA0;1.33</td></tr><tr><td align="left">CDP 2&#xA0;mg/kg and <sc>d</sc>-serine 100&#xA0;nmol/mouse</td><td char="&#xB1;" align="char">17.40&#xA0;&#xB1;&#xA0;1.32</td></tr></tbody></table><table-wrap-foot><p>Data represent the mean&#xA0;&#xB1;&#xA0;SEM; <italic>n</italic>&#xA0;=&#xA0;9&#x2013;12. Chlordiazepoxide (CDP), CGP 37849, L-701,324, <sc>d</sc>-cycloserine and <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) were administered i.p. 60&#xA0;min before the test. <sc>d</sc>-serine was administered i.c.v. 15&#xA0;min before the test</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Discussion</title>
      <p>A number of behavioral data have suggested the involvement of the glutamate-mediated neurotransmission in an anxiolytic-like behavior. The anxiolytic-like activity was demonstrated for different modulatory sites of NMDA receptor complex: for a non-competitive NMDA antagonist, dizocilpine (MK-801) (Dunn et al. <xref ref-type="bibr" rid="CR8">1989</xref>; Sharma and Kulkarni <xref ref-type="bibr" rid="CR40">1993</xref>; Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>), a competitive NMDA antagonist, 2-amino-7-phosphoheptanoic acid (AP7) (P&#x142;a&#x17A;nik et al. <xref ref-type="bibr" rid="CR34">1994</xref>), CGP 37849 (Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR38">2000</xref>), and partial agonists of glycine<sub>B</sub> sites, <sc>d</sc>-cycloserine (Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>) and 1-aminocyclo-propane-carboxylic acid (ACPC) (Trullas et al. <xref ref-type="bibr" rid="CR45">1989</xref>; Trullas et al. <xref ref-type="bibr" rid="CR46">1991</xref>), and antagonist of glycine<sub>B</sub> sites: L-701,324 (Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>; Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR37">1998</xref>; Kotli&#x144;ska and Liljequist <xref ref-type="bibr" rid="CR23">1998</xref>). The anxiolytic-like profile of different NMDA antagonists was similar to that of benzodiazepines (P&#x142;a&#x17A;nik et al. <xref ref-type="bibr" rid="CR34">1994</xref>) and the excitatory amino acid agonist, NMDA, produced anxiogenic-like effects in the elevated plus-maze test (Dunn et al. <xref ref-type="bibr" rid="CR8">1989</xref>). Moreover, genetic studies indicated an anxiolytic-like activity of NR2A subunit of NMDA receptor knockout mice (Boyce-Rustay and Holmes <xref ref-type="bibr" rid="CR5">2006</xref>). Validation of the elevated plus-maze procedure has shown that it is sensitive to drugs that produce anxiolytic or anxiogenic effects in human (Pellow et al. <xref ref-type="bibr" rid="CR33">1985</xref>), including drugs that have non-benzodiazepine sites of action (Pellow <xref ref-type="bibr" rid="CR32">1986</xref>). Moreover, in the clinical study showed useful of memantine (non-competitive NMDA receptor antagonist) augmentation in treatment-resistant obsessive&#x2013;compulsive disorder (Feusner et al. <xref ref-type="bibr" rid="CR11">2009</xref>; Aboujaoude et al. <xref ref-type="bibr" rid="CR1">2009</xref>), <sc>d</sc>-cycloserine (partial agonists of glycine<sub>B</sub> sites) (Hood et al. <xref ref-type="bibr" rid="CR14">1989</xref>; Emmett et al. <xref ref-type="bibr" rid="CR9">1991</xref>) as a potential therapeutic agent for post-traumatic stress disorder and specific phobia (Heresco-Levy et al. <xref ref-type="bibr" rid="CR12">2002</xref>; Ressler et al. <xref ref-type="bibr" rid="CR39">2004</xref>), and riluzole in the treatment of symptoms obsessive&#x2013;compulsive disorder (Coric et al. <xref ref-type="bibr" rid="CR7">2005</xref>) and general anxiety disorder (Mathew et al. <xref ref-type="bibr" rid="CR28">2005</xref>).</p>
      <p>In the present study, we have demonstrated the influence of NMDA receptor ligands on anxiolytic-like activity of CDP in the elevated plus-maze in mice. We have shown that a competitive NMDA antagonist (CGP 37849), partial agonist of the glycine<sub>B</sub> site (<sc>d</sc>-cycloserine) and glycine<sub>B</sub> antagonist (L-701,324) enhanced the anxiolytic-like activity of CDP in the elevated plus-maze. The previous study has shown that CGP 37849 evoked potentially anxiolytic-like effects in the Vogel conflict drinking test, an open field test (P&#x142;a&#x17A;nik et al. <xref ref-type="bibr" rid="CR34">1994</xref>) and in the elevated plus-maze test in rats and its anxiolytic-like activity was abolished by flumazenil (Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR38">2000</xref>). In our study, 0.312&#xA0;mg/kg CGP 37849 produced synergistic effects with CDP (0.5&#xA0;mg/kg) in the elevated plus-maze test in mice. Unfortunately, the side effects produced by competitive and uncompetitive NMDA antagonist (motor impairment, hyperactivity, stereotypy and psychotomimetic actions (Willetts et al. <xref ref-type="bibr" rid="CR49">1990</xref>) limited their potential use for the treatment in humans. After the discovery that the NMDA receptor activity is regulated by co-agonist (glycine or <sc>d</sc>-serine), numerous studies concentrated on this pathway. It is known that a co-agonist site exerts major regulatory roles in the activity of NMDA receptor complex. The binding of the co-agonist (glycine or <sc>d</sc>-serine) is an obligatory requirement for NMDA receptor/channel activity (Johnson and Ascher <xref ref-type="bibr" rid="CR15">1987</xref>; Kleckner and Dingledine <xref ref-type="bibr" rid="CR20">1988</xref>). More recently, studies have shown that selective blockers of the co-agonist site abolish NMDA receptor activity (Kessler et al. <xref ref-type="bibr" rid="CR18">1989</xref>; Kleckner and Dingledine <xref ref-type="bibr" rid="CR21">1989</xref>) and produced pharmacological effects similar to those exerted after the administration of a competitive and non-competitive NMDA antagonist. <sc>d</sc>-Cycloserine has a profile of a partial agonist acting at the glycine binding site (Hood et al. <xref ref-type="bibr" rid="CR14">1989</xref>; Watson et al. <xref ref-type="bibr" rid="CR48">1990</xref>). In the preclinical data <sc>d</sc>-cycloserine exhibits anxiolytic-like effects in the Vogel conflict test (K&#x142;odzi&#x144;ska and Chojnacka-W&#xF3;jcik <xref ref-type="bibr" rid="CR22">2000</xref>), in the elevated plus-maze (time in open arms) (Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>; Ho et al. <xref ref-type="bibr" rid="CR13">2005</xref>; Poleszak et al. <xref ref-type="bibr" rid="CR36">2008</xref>), and in a fear-potentiated startle response test (Anthony and Nevins <xref ref-type="bibr" rid="CR4">1993</xref>) (Campeau et al. <xref ref-type="bibr" rid="CR6">1992</xref>; Fendt et al. <xref ref-type="bibr" rid="CR10">1996</xref>). The glycine<sub>B</sub> receptor antagonist (L-701,324) has produced anxiolytic-like effects in the elevated plus-maze test and the four-plate test (Karcz-Kubicha et al. <xref ref-type="bibr" rid="CR17">1997</xref>; Przegali&#x144;ski et al. <xref ref-type="bibr" rid="CR37">1998</xref>; Kotli&#x144;ska and Liljequist <xref ref-type="bibr" rid="CR23">1998</xref>).</p>
      <p>In our study, the combined treatment with CDP and L-701,324 (a glycine<sub>B</sub> site antagonist) or <sc>d</sc>-cycloserine (a glycine site partial agonist), all at low, ineffective doses, increased the time spent in the open arms of the elevated plus-maze, with no effects on the number of total entries (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Because the obtained data indicate a lack of effect on the locomotor activity, we can assume that this combination produced an anxiolytic-like activity. The anxiolytic-like activity of CDP was reduced by NMDA or by <sc>d</sc>-serine, what suggests the involvement of NMDA receptor complex in the anxiolytic activity of CDP in the elevated plus-maze in mice. The interaction between NMDA and GABAergic neurotransmission in anxiety assessments in animals was shown in other experiments. The anxiolytic-like activity of MK-801 was enhanced by diazepam, antagonized by the benzodiazepine receptor antagonist (Ro-15-1788) and reversed by the anxiogenic agent, <italic>&#x3B2;</italic>-carboline FG-7142 (Sharma and Kulkarni <xref ref-type="bibr" rid="CR40">1993</xref>).</p>
      <p>To summarize, the present study indicates the involvement of the NMDA receptor complex in the anxiolytic-like activity of CDP in the EMP in mice. Our results also suggest that full anxiolysis might be possible with a reduced dose of benzodiazepines when co-administered with NMDA receptor antagonists and this might substantially reduce side effects and the risk of the benzodiazepine dependence. Clinical trials are necessary to determine if such a combination is of a potentially therapeutic value in humans with anxiety disorders.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>This study was supported by Funds for Statutory Activity of Medical University of Lublin, Maria Curie-Sk&#x142;odowska University, Lublin, Institute of Pharmacology, Polish Academy of Sciences, and Jagiellonian University Collegium Medicum, Krak&#xF3;w, Poland.</p>
      <p><bold>Conflict of interest</bold> The authors declare they have no conflict of interest.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aboujaoude</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gamel</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Memantine augmentation in treatment-resistant obsessive&#x2013;compulsive disorder: an open-label trial</article-title>
          <source>J Clin Psychopharmacol</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>51</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1097/JCP.0b013e318192e9a4</pub-id>
          <pub-id pub-id-type="pmid">19142108</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abramowitz</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McKay</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Obsessive&#x2013;compulsive disorder</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>374</volume>
          <fpage>491</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60240-3</pub-id>
          <pub-id pub-id-type="pmid">19665647</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amiel</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mathew</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Glutamate and anxiety disorders</article-title>
          <source>Curr Psychiatry Rep</source>
          <year>2007</year>
          <volume>9</volume>
          <fpage>278</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.1007/s11920-007-0033-7</pub-id>
          <pub-id pub-id-type="pmid">17880858</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anthony</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Nevins</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Anxiolytic-like effects of <italic>N</italic>-methyl-<sc>d</sc>-aspartate-associated glycine receptor ligands in the rat potentiated startle test</article-title>
          <source>Eur J Pharmacol</source>
          <year>1993</year>
          <volume>250</volume>
          <fpage>317</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(93)90397-Z</pub-id>
          <pub-id pub-id-type="pmid">7906654</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyce-Rustay</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice</article-title>
          <source>Neuropsychopharmacology</source>
          <year>2006</year>
          <volume>31</volume>
          <fpage>2405</fpage>
          <lpage>2414</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.npp.1301039</pub-id>
          <pub-id pub-id-type="pmid">16482087</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campeau</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miserendino</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Intra-amygdala infusion of the <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist AP5 blocks acquisition but not expression of fear-potentiated startle to an auditory conditioned stimulus</article-title>
          <source>Behav Neurosci</source>
          <year>1992</year>
          <volume>106</volume>
          <fpage>569</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="doi">10.1037/0735-7044.106.3.569</pub-id>
          <pub-id pub-id-type="pmid">1352104</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coric</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Taskiran</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pittenger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wasylink</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mathalon</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Valentine</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Saksa</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Gueorguieva</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sanacora</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Malison</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Krystal</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial</article-title>
          <source>Biol Psychiatry</source>
          <year>2005</year>
          <volume>58</volume>
          <fpage>424</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.04.043</pub-id>
          <pub-id pub-id-type="pmid">15993857</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dunn</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fielding</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze</article-title>
          <source>Eur J Pharmacol</source>
          <year>1989</year>
          <volume>169</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(89)90811-X</pub-id>
          <pub-id pub-id-type="pmid">2574684</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emmett</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Mick</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Cler</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Iyengar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Actions of <sc>d</sc>-cycloserine at the <italic>N</italic>-methyl-<sc>d</sc>-aspartate-associated glycine receptor site in vivo</article-title>
          <source>Neuropharmacology</source>
          <year>1991</year>
          <volume>30</volume>
          <fpage>1167</fpage>
          <lpage>1171</lpage>
          <pub-id pub-id-type="doi">10.1016/0028-3908(91)90161-4</pub-id>
          <pub-id pub-id-type="pmid">1663594</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fendt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schnitzler</surname>
              <given-names>HU</given-names>
            </name>
          </person-group>
          <article-title>NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response</article-title>
          <source>Eur J Pharmacol</source>
          <year>1996</year>
          <volume>318</volume>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-2999(96)00749-2</pub-id>
          <pub-id pub-id-type="pmid">9007504</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feusner</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kerwin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Saxena</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bystritsky</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial</article-title>
          <source>Psychopharmacol Bull</source>
          <year>2009</year>
          <volume>42</volume>
          <fpage>81</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">19204653</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heresco-Levy</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Javitt</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Goichman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Reshef</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blanaru</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Pilot-controlled trial of <sc>d</sc>-cycloserine for the treatment of post-traumatic stress disorder</article-title>
          <source>Int J Neuropsychopharmacol</source>
          <year>2002</year>
          <volume>5</volume>
          <fpage>301</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1017/S1461145702003061</pub-id>
          <pub-id pub-id-type="pmid">12466030</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>YF</given-names>
            </name>
          </person-group>
          <article-title>Behavioral effects of <sc>d</sc>-cycloserine in rats: the role of anxiety level</article-title>
          <source>Brain Res</source>
          <year>2005</year>
          <volume>1043</volume>
          <fpage>179</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="doi">10.1016/j.brainres.2005.02.057</pub-id>
          <pub-id pub-id-type="pmid">15862531</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hood</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Monahan</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title><sc>d</sc>-cycloserine: a ligand for the <italic>N</italic>-methyl-<sc>d</sc>-aspartate coupled glycine receptor has partial agonist characteristics</article-title>
          <source>Neurosci Lett</source>
          <year>1989</year>
          <volume>98</volume>
          <fpage>91</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1016/0304-3940(89)90379-0</pub-id>
          <pub-id pub-id-type="pmid">2540460</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ascher</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Glycine potentiates the NMDA response in cultured mouse brain neurons</article-title>
          <source>Nature</source>
          <year>1987</year>
          <volume>325</volume>
          <fpage>529</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1038/325529a0</pub-id>
          <pub-id pub-id-type="pmid">2433595</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalueff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nutt</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Role of GABA in memory and anxiety</article-title>
          <source>Depress Anxiety</source>
          <year>1996</year>
          <volume>4</volume>
          <fpage>100</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1520-6394(1996)4:3&lt;100::AID-DA2&gt;3.0.CO;2-K</pub-id>
          <pub-id pub-id-type="pmid">9166638</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karcz-Kubicha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jessa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nazar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pla&#x17A;nik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Danysz</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Anxiolytic activity of glycine-B antagonists and partial agonists&#x2013;no relation to intrinsic activity in the patch clamp</article-title>
          <source>Neuropharmacology</source>
          <year>1997</year>
          <volume>36</volume>
          <fpage>1355</fpage>
          <lpage>1367</lpage>
          <pub-id pub-id-type="doi">10.1016/S0028-3908(97)00130-5</pub-id>
          <pub-id pub-id-type="pmid">9423923</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kessler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Terramani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baudry</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A glycine site associated with <italic>N</italic>-methyl-<sc>d</sc>-aspartic acid receptors: characterization and identification of a new class of antagonists</article-title>
          <source>J Neurochem</source>
          <year>1989</year>
          <volume>52</volume>
          <fpage>1319</fpage>
          <lpage>1328</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.1989.tb01881.x</pub-id>
          <pub-id pub-id-type="pmid">2538568</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kew</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Ionotropic and metabotropic glutamate receptor structure and pharmacology</article-title>
          <source>Psychopharmacology (Berl)</source>
          <year>2005</year>
          <volume>179</volume>
          <fpage>4</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="doi">10.1007/s00213-005-2200-z</pub-id>
          <pub-id pub-id-type="pmid">15731895</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleckner</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Dingledine</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Requirement for glycine in activation of NMDA-receptors expressed in <italic>Xenopus</italic> oocytes</article-title>
          <source>Science</source>
          <year>1988</year>
          <volume>241</volume>
          <fpage>835</fpage>
          <lpage>837</lpage>
          <pub-id pub-id-type="doi">10.1126/science.2841759</pub-id>
          <pub-id pub-id-type="pmid">2841759</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleckner</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Dingledine</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors</article-title>
          <source>Mol Pharmacol</source>
          <year>1989</year>
          <volume>36</volume>
          <fpage>430</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="pmid">2550776</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K&#x142;odzi&#x144;ska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chojnacka-W&#xF3;jcik</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Anticonflict effect of the glycine<sub>B</sub> receptor partial agonist, <sc>d</sc>-cycloserine, in rats. Pharmacological analysis</article-title>
          <source>Psychopharmacology (Berl)</source>
          <year>2000</year>
          <volume>152</volume>
          <fpage>224</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.1007/s002130000547</pub-id>
          <pub-id pub-id-type="pmid">11057527</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kotli&#x144;ska</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liljequist</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324</article-title>
          <source>Psychopharmacology (Berl)</source>
          <year>1998</year>
          <volume>135</volume>
          <fpage>175</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="doi">10.1007/s002130050499</pub-id>
          <pub-id pub-id-type="pmid">9497023</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krystal</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>D&#x2019;Souza</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Petrakis</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Belger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Charney</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Abi-Saab</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Madonick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders</article-title>
          <source>Harv Rev Psychiatry</source>
          <year>1999</year>
          <volume>7</volume>
          <fpage>125</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">10483932</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipman</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Rapid intracerebroventricular injection assisted by an automatic syringe</article-title>
          <source>J Pharmacol Methods</source>
          <year>1980</year>
          <volume>4</volume>
          <fpage>327</fpage>
          <lpage>333</lpage>
          <pub-id pub-id-type="doi">10.1016/0160-5402(80)90052-2</pub-id>
          <pub-id pub-id-type="pmid">7206740</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lister</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>The use of a plus-maze to measure anxiety in the mouse</article-title>
          <source>Psychopharmacology (Berl)</source>
          <year>1987</year>
          <volume>92</volume>
          <fpage>180</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">3110839</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lydiard</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>The role of GABA in anxiety disorders</article-title>
          <source>J Clin Psychiatry</source>
          <year>2003</year>
          <volume>64</volume>
          <issue>Suppl 3</issue>
          <fpage>21</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">12662130</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathew</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Amiel</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Coplan</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Fitterling</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Sackeim</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Gorman</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Open-label trial of riluzole in generalized anxiety disorder</article-title>
          <source>Am J Psychiatry</source>
          <year>2005</year>
          <volume>162</volume>
          <fpage>2379</fpage>
          <lpage>2381</lpage>
          <pub-id pub-id-type="doi">10.1176/appi.ajp.162.12.2379</pub-id>
          <pub-id pub-id-type="pmid">16330605</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemeroff</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
          <article-title>The role of GABA in the pathophysiology and treatment of anxiety disorders</article-title>
          <source>Psychopharmacol Bull</source>
          <year>2003</year>
          <volume>37</volume>
          <fpage>133</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">15131523</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nutt</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Malizia</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>New insights into the role of the GABA<sub>A</sub>-benzodiazepine receptor in psychiatric disorder</article-title>
          <source>Br J Psychiatry</source>
          <year>2001</year>
          <volume>179</volume>
          <fpage>390</fpage>
          <lpage>396</lpage>
          <pub-id pub-id-type="doi">10.1192/bjp.179.5.390</pub-id>
          <pub-id pub-id-type="pmid">11689393</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR31">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parsons</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Danysz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Quack</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Glutamate in CNS disorders as a target for drug development: an update</article-title>
          <source>Drug News Perspect</source>
          <year>1998</year>
          <volume>11</volume>
          <fpage>523</fpage>
          <lpage>569</lpage>
          <pub-id pub-id-type="doi">10.1358/dnp.1998.11.9.863689</pub-id>
          <pub-id pub-id-type="pmid">15616669</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR32">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pellow</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid?</article-title>
          <source>Methods Find Exp Clin Pharmacol</source>
          <year>1986</year>
          <volume>8</volume>
          <fpage>557</fpage>
          <lpage>565</lpage>
          <pub-id pub-id-type="pmid">2877126</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR33">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pellow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chopin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>File</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Briley</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat</article-title>
          <source>J Neurosci Methods</source>
          <year>1985</year>
          <volume>14</volume>
          <fpage>149</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1016/0165-0270(85)90031-7</pub-id>
          <pub-id pub-id-type="pmid">2864480</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR34">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>P&#x142;a&#x17A;nik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pa&#x142;ejko</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nazar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jessa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects of antagonists at the NMDA receptor complex in two models of anxiety</article-title>
          <source>Eur Neuropsychopharmacol</source>
          <year>1994</year>
          <volume>4</volume>
          <fpage>503</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1016/0924-977X(94)90299-2</pub-id>
          <pub-id pub-id-type="pmid">7894261</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR35">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poleszak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Szewczyk</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>K&#x119;dzierska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wla&#x17A;</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pilc</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Antidepressant- and anxiolytic-like activity of magnesium in mice</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>2004</year>
          <volume>78</volume>
          <fpage>7</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2004.01.006</pub-id>
          <pub-id pub-id-type="pmid">15159129</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR36">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poleszak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wla&#x17A;</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wr&#xF3;bel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fidecka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice</article-title>
          <source>Pharmacol Rep</source>
          <year>2008</year>
          <volume>60</volume>
          <fpage>655</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="pmid">19066411</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR37">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Przegali&#x144;ski</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tatarczy&#x144;ska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chojnacka-W&#xF3;jcik</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Anxiolytic- and antidepressant-like effects of an antagonist at glycine<sub>B</sub> receptors</article-title>
          <source>Pol J Pharmacol</source>
          <year>1998</year>
          <volume>50</volume>
          <fpage>349</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">10091720</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR38">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Przegali&#x144;ski</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tatarczy&#x144;ska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chojnacka-W&#xF3;jcik</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats</article-title>
          <source>Neuropharmacology</source>
          <year>2000</year>
          <volume>39</volume>
          <fpage>1858</fpage>
          <lpage>1864</lpage>
          <pub-id pub-id-type="doi">10.1016/S0028-3908(00)00023-X</pub-id>
          <pub-id pub-id-type="pmid">10884566</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR39">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ressler</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Rothbaum</surname>
              <given-names>BO</given-names>
            </name>
            <name>
              <surname>Tannenbaum</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Graap</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zimand</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hodges</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cognitive enhancers as adjuncts to psychotherapy: use of <sc>d</sc>-cycloserine in phobic individuals to facilitate extinction of fear</article-title>
          <source>Arch Gen Psychiatry</source>
          <year>2004</year>
          <volume>61</volume>
          <fpage>1136</fpage>
          <lpage>1144</lpage>
          <pub-id pub-id-type="doi">10.1001/archpsyc.61.11.1136</pub-id>
          <pub-id pub-id-type="pmid">15520361</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR40">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats</article-title>
          <source>Indian J Exp Biol</source>
          <year>1993</year>
          <volume>31</volume>
          <fpage>191</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">8388854</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR41">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sieghart</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Structure and pharmacology of gamma-aminobutyric acid<sub>A</sub> receptor subtypes</article-title>
          <source>Pharmacol Rev</source>
          <year>1995</year>
          <volume>47</volume>
          <fpage>181</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">7568326</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR42">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sieghart</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tretter</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ebert</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jechlinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Adamiker</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Structure and subunit composition of GABA<sub>A</sub> receptors</article-title>
          <source>Neurochem Int</source>
          <year>1999</year>
          <volume>34</volume>
          <fpage>379</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1016/S0197-0186(99)00045-5</pub-id>
          <pub-id pub-id-type="pmid">10397365</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR43">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stahl</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Don&#x2019;t ask, don&#x2019;t tell, but benzodiazepines are still the leading treatments for anxiety disorder</article-title>
          <source>J Clin Psychiatry</source>
          <year>2002</year>
          <volume>63</volume>
          <fpage>756</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="doi">10.4088/JCP.v63n0901</pub-id>
          <pub-id pub-id-type="pmid">12363113</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR44">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tricklebank</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Oles</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Preston</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Iversen</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor</article-title>
          <source>Eur J Pharmacol</source>
          <year>1989</year>
          <volume>167</volume>
          <fpage>127</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(89)90754-1</pub-id>
          <pub-id pub-id-type="pmid">2550253</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR45">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trullas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Skolnick</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>1989</year>
          <volume>34</volume>
          <fpage>313</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1016/0091-3057(89)90317-1</pub-id>
          <pub-id pub-id-type="pmid">2576136</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR46">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trullas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Folio</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boje</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Skolnick</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title><sc>1</sc>-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models</article-title>
          <source>Eur J Pharmacol</source>
          <year>1991</year>
          <volume>203</volume>
          <fpage>379</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-2999(91)90894-V</pub-id>
          <pub-id pub-id-type="pmid">1685448</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR47">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhlenhuth</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Balter</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Ban</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</article-title>
          <source>J Clin Psychopharmacol</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>23S</fpage>
          <lpage>29S</lpage>
          <pub-id pub-id-type="doi">10.1097/00004714-199912002-00005</pub-id>
          <pub-id pub-id-type="pmid">10587281</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR48">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watson</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Bolanowski</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Baganoff</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Deppeler</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Lanthorn</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title><sc>d</sc>-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in <italic>Xenopus</italic> oocytes</article-title>
          <source>Brain Res</source>
          <year>1990</year>
          <volume>510</volume>
          <fpage>158</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-8993(90)90745-W</pub-id>
          <pub-id pub-id-type="pmid">2157524</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR49">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willetts</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Balster</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Leander</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>The behavioral pharmacology of NMDA receptor antagonists</article-title>
          <source>Trends Pharmacol Sci</source>
          <year>1990</year>
          <volume>11</volume>
          <fpage>423</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1016/0165-6147(90)90150-7</pub-id>
          <pub-id pub-id-type="pmid">2147794</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR50">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Emmett</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Mick</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Iyengar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>In vivo modulation of the <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor complex by <sc>d</sc>-serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP</article-title>
          <source>J Neurochem</source>
          <year>1989</year>
          <volume>53</volume>
          <fpage>979</fpage>
          <lpage>981</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1471-4159.1989.tb11803.x</pub-id>
          <pub-id pub-id-type="pmid">2547911</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR51">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Hawkinson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Goodnough</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Formation of <sc>d</sc>-serine from <sc>l</sc>-phosphoserine in brain synaptosomes</article-title>
          <source>J Neurochem</source>
          <year>1996</year>
          <volume>67</volume>
          <fpage>1485</fpage>
          <lpage>1490</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1471-4159.1996.67041485.x</pub-id>
          <pub-id pub-id-type="pmid">8858931</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
